{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T10:08:50Z","timestamp":1793614130330,"version":"4.5.0"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Bari Aldo Moro"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The term non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common type of chronic liver disease. NAFLD points to excessive hepatic fat storage and no evidence of secondary hepatic fat accumulation in patients with \u201cno or little alcohol consumption\u201d. Both the etiology and pathogenesis of NAFLD are largely unknown, and a definitive therapy is lacking. Since NAFLD is very often and closely associated with metabolic dysfunctions, a consensus process is ongoing to shift the acronym NAFLD to MAFLD, i.e., metabolic-associated fatty liver disease. The change in terminology is likely to improve the classification of affected individuals, the disease awareness, the comprehension of the terminology and pathophysiological aspects involved, and the choice of more personalized therapeutic approaches while avoiding the intrinsic stigmatization due to the term \u201cnon-alcoholic\u201d. Even more recently, other sub-classifications have been proposed to concentrate the heterogeneous causes of fatty liver disease under one umbrella. While awaiting additional validation studies in this field, we discuss the main reasons underlying this important shift of paradigm.<\/jats:p>","DOI":"10.1007\/s11739-023-03203-0","type":"journal-article","created":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T01:17:52Z","timestamp":1676683072000},"page":"993-1006","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5359-1471","authenticated-orcid":false,"given":"Piero","family":"Portincasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"issue":"7","key":"3203_CR1","first-page":"434","volume":"55","author":"J Ludwig","year":"1980","unstructured":"Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic proceedings. Mayo Clinic 55(7):434\u2013438","journal-title":"Mayo Clinic"},{"key":"3203_CR2","first-page":"283","volume":"8","author":"F Schaffner","year":"1986","unstructured":"Schaffner F, Thaler H (1986) Nonalcoholic fatty liver disease. Prog Liver Dis 8:283\u2013298","journal-title":"Prog Liver Dis"},{"issue":"10","key":"3203_CR3","doi-asserted-by":"publisher","first-page":"e13338","DOI":"10.1111\/eci.13338","volume":"50","author":"P Portincasa","year":"2020","unstructured":"Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A (2020) COVID-19 and non-alcoholic fatty liver disease: two intersecting pandemics. Eur J Clin Invest 50(10):e13338. https:\/\/doi.org\/10.1111\/eci.13338","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"3203_CR4","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.clinre.2019.04.005","volume":"43","author":"E Molina-Molina","year":"2019","unstructured":"Molina-Molina E, Krawczyk M, Stachowska E, Lammert F, Portincasa P (2019) Non-alcoholic fatty liver disease in non-obese individuals: prevalence, pathogenesis and treatment. Clin Res Hepatol Gastroenterol 43(6):638\u2013645. https:\/\/doi.org\/10.1016\/j.clinre.2019.04.005","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"3203_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1055\/s-0033-1358525","volume":"33","author":"M Krawczyk","year":"2013","unstructured":"Krawczyk M, Portincasa P, Lammert F (2013) PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease. Semin Liver Dis 33(4):369\u2013379. https:\/\/doi.org\/10.1055\/s-0033-1358525","journal-title":"Semin Liver Dis"},{"issue":"5","key":"3203_CR6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.bpg.2010.08.005","volume":"24","author":"M Krawczyk","year":"2010","unstructured":"Krawczyk M, Bonfrate L, Portincasa P (2010) Nonalcoholic fatty liver disease. Best practice & research. Clin Gastroenterol 24(5):695\u2013708. https:\/\/doi.org\/10.1016\/j.bpg.2010.08.005","journal-title":"Clin Gastroenterol"},{"issue":"7","key":"3203_CR7","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher G, Tilg H, Byrne CD (2021) Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 6(7):578\u2013588. https:\/\/doi.org\/10.1016\/S2468-1253(21)00020-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"3203_CR8","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the L, European Association for the Study of D, and European Association for the Study of O","year":"2016","unstructured":"European Association for the Study of the L, European Association for the Study of D, and European Association for the Study of O (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64(6):1388\u20131402. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004","journal-title":"J Hepatol"},{"issue":"1","key":"3203_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ (2018) The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67(1):328\u2013357. https:\/\/doi.org\/10.1002\/hep.29367","journal-title":"Hepatology"},{"issue":"1","key":"3203_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wong VW-S, Dufour J-F, Schattenberg JM (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73(1):202\u2013209","journal-title":"J Hepatol"},{"issue":"7","key":"3203_CR11","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, International Consensus P (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158(7):1999-2014 e1991. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312","journal-title":"Gastroenterology"},{"issue":"5","key":"3203_CR12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S2468-1253(22)00062-0","volume":"7","author":"N Mendez-Sanchez","year":"2022","unstructured":"Mendez-Sanchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M, Global multi-stakeholder consensus on the redefinition of fatty liver d (2022) Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol 7(5):388\u2013390. https:\/\/doi.org\/10.1016\/S2468-1253(22)00062-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"3203_CR13","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, Vos MB (2019) Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 69(6):2672\u20132682. https:\/\/doi.org\/10.1002\/hep.30251","journal-title":"Hepatology"},{"issue":"3","key":"3203_CR14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.20524\/aog.2021.0604","volume":"34","author":"E Cholongitas","year":"2021","unstructured":"Cholongitas E, Pavlopoulou I, Papatheodoridi M, Markakis GE, Bouras E, Haidich AB, Papatheodoridis G (2021) Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. Ann Gastroenterol 34(3):404\u2013414. https:\/\/doi.org\/10.20524\/aog.2021.0604","journal-title":"Ann Gastroenterol"},{"key":"3203_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-022-03139-x","author":"A Rojano","year":"2022","unstructured":"Rojano A, Sena E, Manzano-Nunez R, Pericas JM, Ciudin A (2022) NAFLD as the metabolic hallmark of obesity. Intern Emerg Med. https:\/\/doi.org\/10.1007\/s11739-022-03139-x","journal-title":"Intern Emerg Med"},{"issue":"1","key":"3203_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ (2018) Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67(1):123\u2013133. https:\/\/doi.org\/10.1002\/hep.29466","journal-title":"Hepatology"},{"issue":"4","key":"3203_CR17","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H (2018) Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol 69(4):896\u2013904. https:\/\/doi.org\/10.1016\/j.jhep.2018.05.036","journal-title":"J Hepatol"},{"issue":"6","key":"3203_CR18","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1002\/hep.30946","volume":"70","author":"R Loomba","year":"2019","unstructured":"Loomba R, Adams LA (2019) The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology 70(6):1885\u20131888. https:\/\/doi.org\/10.1002\/hep.30946","journal-title":"Hepatology"},{"issue":"17","key":"3203_CR19","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1001\/jama.2019.2276","volume":"321","author":"T Wong","year":"2019","unstructured":"Wong T, Dang K, Ladhani S, Singal AK, Wong RJ (2019) Prevalence of alcoholic fatty liver disease among adults in the United States, 2001\u20132016. JAMA 321(17):1723\u20131725. https:\/\/doi.org\/10.1001\/jama.2019.2276","journal-title":"JAMA"},{"issue":"10290","key":"3203_CR20","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M (2021) Non-alcoholic fatty liver disease. Lancet 397(10290):2212\u20132224. https:\/\/doi.org\/10.1016\/S0140-6736(20)32511-3","journal-title":"Lancet"},{"issue":"10","key":"3203_CR21","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, Kim HC (2021) Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol 19(10):2138-2147 e2110. https:\/\/doi.org\/10.1016\/j.cgh.2020.12.022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"3203_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/cld.900","volume":"16","author":"AA Li","year":"2020","unstructured":"Li AA, Kim D, Ahmed A (2020) Association of sarcopenia and NAFLD: an overview. Clin Liver Dis (Hoboken) 16(2):73\u201376. https:\/\/doi.org\/10.1002\/cld.900","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"3203_CR23","doi-asserted-by":"crossref","unstructured":"Polyzos SA, and Mantzoros CS (2020). Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). Metab-Clin Exp 111","DOI":"10.1016\/j.metabol.2020.154318"},{"issue":"5","key":"3203_CR24","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.jhep.2021.06.045","volume":"75","author":"H Hagstrom","year":"2021","unstructured":"Hagstrom H, Simon TG, Roelstraete B, Stephansson O, Soderling J, Ludvigsson JF (2021) Maternal obesity increases the risk and severity of NAFLD in offspring. J Hepatol 75(5):1042\u20131048. https:\/\/doi.org\/10.1016\/j.jhep.2021.06.045","journal-title":"J Hepatol"},{"issue":"1","key":"3203_CR25","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1038\/s41467-018-06929-0","volume":"9","author":"TK Soderborg","year":"2018","unstructured":"Soderborg TK, Clark SE, Mulligan CE, Janssen RC, Babcock L, Ir D, Young B, Krebs N, Lemas DJ, Johnson LK, Weir T, Lenz LL, Frank DN, Hernandez TL, Kuhn KA, D\u2019Alessandro A, Barbour LA, El Kasmi KC, Friedman JE (2018) The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD. Nat Commun 9(1):4462. https:\/\/doi.org\/10.1038\/s41467-018-06929-0","journal-title":"Nat Commun"},{"issue":"4","key":"3203_CR26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1055\/s-0041-1730927","volume":"41","author":"M Arrese","year":"2021","unstructured":"Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE (2021) Insights into nonalcoholic fatty-liver disease heterogeneity. Semin Liver Dis 41(4):421\u2013434. https:\/\/doi.org\/10.1055\/s-0041-1730927","journal-title":"Semin Liver Dis"},{"issue":"10","key":"3203_CR27","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1111\/liv.15024","volume":"41","author":"G Semmler","year":"2021","unstructured":"Semmler G, Datz C, Reiberger T, Trauner M (2021) Diet and exercise in NAFLD\/NASH: beyond the obvious. Liver Int 41(10):2249\u20132268. https:\/\/doi.org\/10.1111\/liv.15024","journal-title":"Liver Int"},{"key":"3203_CR28","doi-asserted-by":"publisher","first-page":"155136","DOI":"10.1016\/j.metabol.2022.155136","volume":"129","author":"AM Angelidi","year":"2022","unstructured":"Angelidi AM, Papadaki A, Nolen-Doerr E, Boutari C, Mantzoros CS (2022) The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: a systematic review of randomised controlled trials. Metab Clin Exp 129:155136. https:\/\/doi.org\/10.1016\/j.metabol.2022.155136","journal-title":"Metab Clin Exp"},{"key":"3203_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15416","author":"FR Li","year":"2022","unstructured":"Li FR, Liao J, Zhu B, Li X, Cheng Z, Jin C, Mo C, Wu X, Li Q, Liang F (2022) Long-term exposure to air pollution and incident non-alcoholic fatty liver disease and cirrhosis: a cohort study. Liver Int. https:\/\/doi.org\/10.1111\/liv.15416","journal-title":"Liver Int"},{"issue":"3","key":"3203_CR30","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jhep.2021.10.016","volume":"76","author":"B Guo","year":"2022","unstructured":"Guo B, Guo Y, Nima Q, Feng Y, Wang Z, Lu R, Baimayangji MY, Zhou J, Xu H, Chen L, Chen G, Li S, Tong H, Ding X, Zhao X, Cohort CM-E, collaborative g (2022) Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease. J Hepatol 76(3):518\u2013525. https:\/\/doi.org\/10.1016\/j.jhep.2021.10.016","journal-title":"J Hepatol"},{"issue":"19","key":"3203_CR31","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.2174\/0929867324666170518095736","volume":"26","author":"A Di Ciaula","year":"2019","unstructured":"Di Ciaula A, Portincasa P (2019) Diet and contaminants: driving the rise to obesity epidemics? Curr Med Chem 26(19):3471\u20133482. https:\/\/doi.org\/10.2174\/0929867324666170518095736","journal-title":"Curr Med Chem"},{"issue":"3","key":"3203_CR32","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/hep.31417","volume":"73","author":"LJM Alferink","year":"2021","unstructured":"Alferink LJM, Radjabzadeh D, Erler NS, Vojinovic D, Medina-Gomez C, Uitterlinden AG, de Knegt RJ, Amin N, Ikram MA, Janssen HLA, Kiefte-de Jong JC, Metselaar HJ, van Duijn CM, Kraaij R, Darwish Murad S (2021) Microbiomics, metabolomics, predicted metagenomics, and hepatic steatosis in a population-based study of 1,355 adults. Hepatology 73(3):968\u2013982. https:\/\/doi.org\/10.1002\/hep.31417","journal-title":"Hepatology"},{"issue":"9","key":"3203_CR33","doi-asserted-by":"publisher","first-page":"e13276","DOI":"10.1111\/eci.13276","volume":"50","author":"W Smyk","year":"2020","unstructured":"Smyk W, Janik MK, Portincasa P, Milkiewicz P, Lammert F, Krawczyk M (2020) COVID-19: focus on the lungs but do not forget the gastrointestinal tract. Eur J Clin Investig 50(9):e13276","journal-title":"Eur J Clin Investig"},{"issue":"7","key":"3203_CR34","doi-asserted-by":"publisher","first-page":"e13768","DOI":"10.1111\/eci.13768","volume":"52","author":"A Di Ciaula","year":"2022","unstructured":"Di Ciaula A, Bonfrate L, Portincasa P (2022) The role of microbiota in nonalcoholic fatty liver disease. Eur J Clin Invest 52(7):e13768. https:\/\/doi.org\/10.1111\/eci.13768","journal-title":"Eur J Clin Invest"},{"key":"3203_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejim.2017.10.020","volume":"48","author":"A Vecchie","year":"2018","unstructured":"Vecchie A, Dallegri F, Carbone F, Bonaventura A, Liberale L, Portincasa P, Fruhbeck G, Montecucco F (2018) Obesity phenotypes and their paradoxical association with cardiovascular diseases. Eur J Intern Med 48:6\u201317. https:\/\/doi.org\/10.1016\/j.ejim.2017.10.020","journal-title":"Eur J Intern Med"},{"issue":"12","key":"3203_CR36","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1097\/MEG.0b013e32833f14a1","volume":"22","author":"S Francque","year":"2010","unstructured":"Francque S, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, Van Gaal L, Michielsen P (2010) Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. Eur J Gastroenterol Hepatol 22(12):1449\u20131457. https:\/\/doi.org\/10.1097\/MEG.0b013e32833f14a1","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3203_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejim.2021.03.036","volume":"89","author":"A Di Ciaula","year":"2021","unstructured":"Di Ciaula A, Carbone F, Shanmugham H, Molina-Molina E, Bonfrate L, Ministrini S, Montecucco F, Portincasa P (2021) Adiponectin involved in portal flow hepatic extraction of 13C-methacetin in obesity and non-alcoholic fatty liver. Eur J Intern Med 89:56\u201364. https:\/\/doi.org\/10.1016\/j.ejim.2021.03.036","journal-title":"Eur J Intern Med"},{"issue":"4","key":"3203_CR38","doi-asserted-by":"publisher","first-page":"e32785","DOI":"10.1371\/journal.pone.0032785","volume":"7","author":"M Pasarin","year":"2012","unstructured":"Pasarin M, La Mura V, Gracia-Sancho J, Garcia-Caldero H, Rodriguez-Vilarrupla A, Garcia-Pagan JC, Bosch J, Abraldes JG (2012) Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. PLoS ONE 7(4):e32785. https:\/\/doi.org\/10.1371\/journal.pone.0032785","journal-title":"PLoS ONE"},{"key":"3203_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.37349\/emed.2020.00011","volume":"1","author":"M Ryou","year":"2020","unstructured":"Ryou M, Stylopoulos N, Baffy G (2020) Nonalcoholic fatty liver disease and portal hypertension. Explor Med 1:149\u2013169. https:\/\/doi.org\/10.37349\/emed.2020.00011","journal-title":"Explor Med"},{"issue":"10","key":"3203_CR40","doi-asserted-by":"publisher","first-page":"5375","DOI":"10.3390\/ijms22105375","volume":"22","author":"A Di Ciaula","year":"2021","unstructured":"Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ-H, Portincasa P (2021) Nonalcoholic fatty liver disease (NAFLD). Mitochondria as players and targets of therapies? Int J Mol Sci 22(10):5375","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3203_CR41","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","volume":"13","author":"ME Rinella","year":"2016","unstructured":"Rinella ME, Sanyal AJ (2016) Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol 13(4):196\u2013205. https:\/\/doi.org\/10.1038\/nrgastro.2016.3","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3203_CR42","first-page":"387","volume-title":"Gallstones. Recent advances in epidemiology, pathogenesis, diagnosis and management","author":"P Portincasa","year":"2017","unstructured":"Portincasa P, Wang DQH (2017) Nonalcoholic fatty liver and gallstone disease. In: Wang DQH, Portincasa P (eds) Gallstones. Recent advances in epidemiology, pathogenesis, diagnosis and management. Nova Science Publisher Inc, USA, pp 387\u2013414"},{"key":"3203_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-3-319-73344-9_7","volume-title":"Mitochondrial biology and experimental therapeutics","author":"I Grattagliano","year":"2018","unstructured":"Grattagliano I, De Bari O, Di Palo D, Montecucco F, Carbone F, Oliveira P, Wang DQH, Portincasa P (2018) Mitochondria in liver diseases. In: Oliveira P (ed) Mitochondrial biology and experimental therapeutics. Springer Nature, Berlin, pp 91\u2013126"},{"issue":"12","key":"3203_CR44","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.tem.2019.08.006","volume":"30","author":"Z Chen","year":"2019","unstructured":"Chen Z, Yu Y, Cai J, Li H (2019) Emerging molecular targets for treatment of nonalcoholic fatty liver disease. Trends Endocrinol Metab: TEM 30(12):903\u2013914. https:\/\/doi.org\/10.1016\/j.tem.2019.08.006","journal-title":"Trends Endocrinol Metab: TEM"},{"issue":"5","key":"3203_CR45","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, Stal P, Wong VW, Kechagias S, Hultcrantz R, Loomba R (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 65(5):1557\u20131565. https:\/\/doi.org\/10.1002\/hep.29085","journal-title":"Hepatology"},{"issue":"8","key":"3203_CR46","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.3390\/jcm9082648","volume":"9","author":"A Di Ciaula","year":"2020","unstructured":"Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P (2020) Liver steatosis, gut-liver axis, microbiome and environmental factors. A never-ending bidirectional cross-talk. J Clin Med 9(8):2648. https:\/\/doi.org\/10.3390\/jcm9082648","journal-title":"J Clin Med"},{"issue":"7","key":"3203_CR47","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","volume":"142","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ, American Gastroenterological A, American Association for the Study of Liver D, and American College of G (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American gastroenterological association, American association for the study of liver diseases, and American college of gastroenterology. Gastroenterology 142(7):1592\u20131609. https:\/\/doi.org\/10.1053\/j.gastro.2012.04.001","journal-title":"Gastroenterology"},{"key":"3203_CR48","doi-asserted-by":"publisher","first-page":"154439","DOI":"10.1016\/j.metabol.2020.154439","volume":"115","author":"J Blomdahl","year":"2021","unstructured":"Blomdahl J, Nasr P, Ekstedt M, Kechagias S (2021) Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. Metab Clin Exp 115:154439","journal-title":"Metab Clin Exp"},{"key":"3203_CR49","doi-asserted-by":"publisher","first-page":"7927685","DOI":"10.1155\/2017\/7927685","volume":"2017","author":"PJ Patel","year":"2017","unstructured":"Patel PJ, Smith D, Connor JP, Horsfall LU, Hayward KL, Hossain F, Williams S, Johnson T, Stuart KA, Brown NN, Saad N, Clouston AD, Irvine KM, Russell AW, Valery PC, Powell EE (2017) Alcohol consumption in diabetic patients with nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol 2017:7927685. https:\/\/doi.org\/10.1155\/2017\/7927685","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"5","key":"3203_CR50","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.3390\/ijms23052636","volume":"23","author":"A Di Ciaula","year":"2022","unstructured":"Di Ciaula A, Bonfrate L, Krawczyk M, Fruhbeck G, Portincasa P (2022) Synergistic and detrimental effects of alcohol intake on progression of liver steatosis. Int J Mol Sci 23(5):2636. https:\/\/doi.org\/10.3390\/ijms23052636","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3203_CR51","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s10096-014-2123-x","volume":"33","author":"JF Li","year":"2014","unstructured":"Li JF, Qu F, Zheng SJ, Wu HL, Liu M, Liu S, Ren Y, Ren F, Chen Y, Duan ZP, Zhang JL (2014) Elevated plasma sphingomyelin (d18:1\/22:0) is closely related to hepatic steatosis in patients with chronic hepatitis C virus infection. Eur J Clin Microbiol Infect Dis 33(10):1725\u20131732. https:\/\/doi.org\/10.1007\/s10096-014-2123-x","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"3203_CR52","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00535-009-0133-8","volume":"45","author":"K Yasui","year":"2010","unstructured":"Yasui K, Harano Y, Mitsuyoshi H, Tsuji K, Endo M, Nakajima T, Minami M, Itoh Y, Zen Y, Nakanuma Y, Yoshikawa T, Okanoue T (2010) Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. J Gastroenterol 45(1):95\u2013104. https:\/\/doi.org\/10.1007\/s00535-009-0133-8","journal-title":"J Gastroenterol"},{"issue":"2","key":"3203_CR53","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1478-3231.2005.01219.x","volume":"26","author":"WY Jian","year":"2006","unstructured":"Jian WY, Shu Chen L, Gui Qiang W (2006) Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int 26(2):166\u2013172. https:\/\/doi.org\/10.1111\/j.1478-3231.2005.01219.x","journal-title":"Liver Int"},{"issue":"2","key":"3203_CR54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1046\/j.1440-1746.2001.02407.x","volume":"16","author":"SJ Hwang","year":"2001","unstructured":"Hwang SJ, Luo JC, Chu CW, Lai CR, Lu CL, Tsay SH, Wu JC, Chang FY, Lee SD (2001) Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol 16(2):190\u2013195. https:\/\/doi.org\/10.1046\/j.1440-1746.2001.02407.x","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"3203_CR55","doi-asserted-by":"publisher","first-page":"789","DOI":"10.5604\/16652681.1171749","volume":"14","author":"SK Satapathy","year":"2015","unstructured":"Satapathy SK, Kuwajima V, Nadelson J, Atiq O, Sanyal AJ (2015) Drug-induced fatty liver disease: an overview of pathogenesis and management. Ann Hepatol 14(6):789\u2013806. https:\/\/doi.org\/10.5604\/16652681.1171749","journal-title":"Ann Hepatol"},{"issue":"1","key":"3203_CR56","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jhep.2015.01.034","volume":"63","author":"AF Stattermayer","year":"2015","unstructured":"Stattermayer AF, Traussnigg S, Dienes HP, Aigner E, Stauber R, Lackner K, Hofer H, Stift J, Wrba F, Stadlmayr A, Datz C, Strasser M, Maieron A, Trauner M, Ferenci P (2015) Hepatic steatosis in Wilson disease\u2013role of copper and PNPLA3 mutations. J Hepatol 63(1):156\u2013163. https:\/\/doi.org\/10.1016\/j.jhep.2015.01.034","journal-title":"J Hepatol"},{"issue":"2","key":"3203_CR57","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41430-019-0455-4","volume":"74","author":"T Jordan","year":"2020","unstructured":"Jordan T, Popovic P, Rotovnik Kozjek N (2020) Liver steatosis in adult patients on home parenteral nutrition. Eur J Clin Nutr 74(2):255\u2013260. https:\/\/doi.org\/10.1038\/s41430-019-0455-4","journal-title":"Eur J Clin Nutr"},{"key":"3203_CR58","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-1-0716-1433-4_12","volume":"2310","author":"I Grattagliano","year":"2021","unstructured":"Grattagliano I, Di Ciaula A, Baj J, Molina-Molina E, Shanmugam H, Garruti G, Wang DQ, Portincasa P (2021) Protocols for mitochondria as the target of pharmacological therapy in the context of nonalcoholic fatty liver disease (NAFLD). Methods Mol Biol 2310:201\u2013246. https:\/\/doi.org\/10.1007\/978-1-0716-1433-4_12","journal-title":"Methods Mol Biol"},{"issue":"6 Pt 2","key":"3203_CR59","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1111\/j.1753-4887.2007.tb00329.x","volume":"65","author":"P Angulo","year":"2007","unstructured":"Angulo P (2007) Obesity and nonalcoholic fatty liver disease. Nutr Rev 65(6 Pt 2):S57-63. https:\/\/doi.org\/10.1111\/j.1753-4887.2007.tb00329.x","journal-title":"Nutr Rev"},{"issue":"10","key":"3203_CR60","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/j.1440-1746.2012.07222.x","volume":"27","author":"CJ Liu","year":"2012","unstructured":"Liu CJ (2012) Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol 27(10):1555\u20131560. https:\/\/doi.org\/10.1111\/j.1440-1746.2012.07222.x","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"3203_CR61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15(1):11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"3203_CR62","doi-asserted-by":"publisher","first-page":"e13811","DOI":"10.1111\/eci.13811","volume":"52","author":"P Yarnoz-Esquiroz","year":"2022","unstructured":"Yarnoz-Esquiroz P, Olazaran L, Aguas-Ayesa M, Perdomo CM, Garcia-Goni M, Silva C, Fernandez-Formoso JA, Escalada J, Montecucco F, Portincasa P, Fruhbeck G (2022) \u201cObesities\u201d: position statement on a complex disease entity with multifaceted drivers. Eur J Clin Investig 52(7):e13811. https:\/\/doi.org\/10.1111\/eci.13811","journal-title":"Eur J Clin Investig"},{"issue":"3","key":"3203_CR63","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34(3):274\u2013285. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04724.x","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3203_CR64","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","volume":"140","author":"CD Williams","year":"2011","unstructured":"Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA (2011) Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140(1):124\u2013131. https:\/\/doi.org\/10.1053\/j.gastro.2010.09.038","journal-title":"Gastroenterology"},{"issue":"1","key":"3203_CR65","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"3203_CR66","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62(1 Suppl):S47-64. https:\/\/doi.org\/10.1016\/j.jhep.2014.12.012","journal-title":"J Hepatol"},{"issue":"6","key":"3203_CR67","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.cgh.2011.03.020","volume":"9","author":"ZM Younossi","year":"2011","unstructured":"Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M (2011) Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 9(6):524\u2013530. https:\/\/doi.org\/10.1016\/j.cgh.2011.03.020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"3203_CR68","doi-asserted-by":"publisher","first-page":"e12958","DOI":"10.1111\/eci.12958","volume":"48","author":"E Molina-Molina","year":"2018","unstructured":"Molina-Molina E, Lunardi Baccetto R, Wang DQ, de Bari O, Krawczyk M, Portincasa P (2018) Exercising the hepatobiliary-gut axis. The impact of physical activity performance. Eur J Clin Investig 48(8):e12958. https:\/\/doi.org\/10.1111\/eci.12958","journal-title":"Eur J Clin Investig"},{"issue":"5","key":"3203_CR69","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H (2020) Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology 71(5):1851\u20131864. https:\/\/doi.org\/10.1002\/hep.31150","journal-title":"Hepatology"},{"issue":"1","key":"3203_CR70","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"A Afshin","year":"2017","unstructured":"Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, Marczak L, Mokdad AH, Moradi-Lakeh M, Naghavi M, Salama JS, Vos T, Abate KH, Abbafati C, Ahmed MB, Al-Aly Z, Alkerwi A, Al-Raddadi R, Amare AT, Amberbir A, Amegah AK, Amini E, Amrock SM, Anjana RM, Arnlov J, Asayesh H, Banerjee A, Barac A, Baye E, Bennett DA, Beyene AS, Biadgilign S, Biryukov S, Bjertness E, Boneya DJ, Campos-Nonato I, Carrero JJ, Cecilio P, Cercy K, Ciobanu LG, Cornaby L, Damtew SA, Dandona L, Dandona R, Dharmaratne SD, Duncan BB, Eshrati B, Esteghamati A, Feigin VL, Fernandes JC, Furst T, Gebrehiwot TT, Gold A, Gona PN, Goto A, Habtewold TD, Hadush KT, Hafezi-Nejad N, Hay SI, Horino M, Islami F, Kamal R, Kasaeian A, Katikireddi SV, Kengne AP, Kesavachandran CN, Khader YS, Khang YH, Khubchandani J, Kim D, Kim YJ, Kinfu Y, Kosen S, Ku T, Defo BK, Kumar GA, Larson HJ, Leinsalu M, Liang X, Lim SS, Liu P, Lopez AD, Lozano R, Majeed A, Malekzadeh R, Malta DC, Mazidi M, McAlinden C, McGarvey ST, Mengistu DT, Mensah GA, Mensink GBM, Mezgebe HB, Mirrakhimov EM, Mueller UO, Noubiap JJ, Obermeyer CM, Ogbo FA, Owolabi MO, Patton GC, Pourmalek F, Qorbani M, Rafay A, Rai RK, Ranabhat CL, Reinig N, Safiri S, Salomon JA, Sanabria JR, Santos IS, Sartorius B, Sawhney M, Schmidhuber J, Schutte AE, Schmidt MI, Sepanlou SG, Shamsizadeh M, Sheikhbahaei S, Shin MJ, Shiri R, Shiue I, Roba HS, Silva DAS, Silverberg JI, Singh JA, Stranges S, Swaminathan S, Tabares-Seisdedos R, Tadese F, Tedla BA, Tegegne BS, Terkawi AS, Thakur JS, Tonelli M, Topor-Madry R, Tyrovolas S, Ukwaja KN, Uthman OA, Vaezghasemi M, Vasankari T, Vlassov VV, Vollset SE, Weiderpass E, Werdecker A, Wesana J, Westerman R, Yano Y, Yonemoto N, Yonga G, Zaidi Z, Zenebe ZM, Zipkin B, Murray CJL, GBD 215 Obesity Collaborators (2017) Health effects of overweight and obesity in 195 Countries over 25 years. New Engl J Med 377(1):13\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1614362","journal-title":"New Engl J Med"},{"issue":"4","key":"3203_CR71","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 71(4):793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021","journal-title":"J Hepatol"},{"issue":"2","key":"3203_CR72","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00125-019-05024-3","volume":"63","author":"M Brouwers","year":"2020","unstructured":"Brouwers M, Simons N, Stehouwer CDA, Isaacs A (2020) Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia 63(2):253\u2013260. https:\/\/doi.org\/10.1007\/s00125-019-05024-3","journal-title":"Diabetologia"},{"issue":"7","key":"3203_CR73","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/liv.14461","volume":"40","author":"X Cai","year":"2020","unstructured":"Cai X, Zheng S, Liu Y, Zhang Y, Lu J, Huang Y (2020) Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation. Liver Int 40(7):1594\u20131600. https:\/\/doi.org\/10.1111\/liv.14461","journal-title":"Liver Int"},{"issue":"7","key":"3203_CR74","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","volume":"15","author":"QM Anstee","year":"2018","unstructured":"Anstee QM, Mantovani A, Tilg H, Targher G (2018) Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 15(7):425\u2013439. https:\/\/doi.org\/10.1038\/s41575-018-0010-0","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"3203_CR75","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/s2468-1253(18)30077-3","volume":"3","author":"EA Tsochatzis","year":"2018","unstructured":"Tsochatzis EA, Newsome PN (2018) Non-alcoholic fatty liver disease and the interface between primary and secondary care. Lancet Gastroenterol Hepatol 3(7):509\u2013517. https:\/\/doi.org\/10.1016\/s2468-1253(18)30077-3","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"3203_CR76","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, Racila A, Hunt S, Beckerman R (2016) The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64(5):1577\u20131586. https:\/\/doi.org\/10.1002\/hep.28785","journal-title":"Hepatology"},{"issue":"5","key":"3203_CR77","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/hep.31173","volume":"72","author":"JM Paik","year":"2020","unstructured":"Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM (2020) Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology 72(5):1605\u20131616. https:\/\/doi.org\/10.1002\/hep.31173","journal-title":"Hepatology"},{"issue":"4","key":"3203_CR78","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.cgh.2016.08.028","volume":"15","author":"D Kim","year":"2017","unstructured":"Kim D, Kim WR (2017) Nonobese fatty liver disease. Clin Gastroenterol Hepatol 15(4):474\u2013485. https:\/\/doi.org\/10.1016\/j.cgh.2016.08.028","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"3203_CR79","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S (2020) Nonalcoholic steatohepatitis: a review. JAMA 323(12):1175\u20131183. https:\/\/doi.org\/10.1001\/jama.2020.2298","journal-title":"JAMA"},{"issue":"6","key":"3203_CR80","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cgh.2011.12.039","volume":"10","author":"M Stepanova","year":"2012","unstructured":"Stepanova M, Younossi ZM (2012) Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 10(6):646\u2013650. https:\/\/doi.org\/10.1016\/j.cgh.2011.12.039","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3203_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/nu14081597","author":"V Catalan","year":"2022","unstructured":"Catalan V, Aviles-Olmos I, Rodriguez A, Becerril S, Fernandez-Formoso JA, Kiortsis D, Portincasa P, Gomez-Ambrosi J, Fruhbeck G (2022) Time to consider the \u201cexposome hypothesis\u201d in the development of the obesity pandemic. Nutrients. https:\/\/doi.org\/10.3390\/nu14081597","journal-title":"Nutrients"},{"issue":"14","key":"3203_CR82","doi-asserted-by":"publisher","first-page":"7702","DOI":"10.3390\/ijms22147702","volume":"22","author":"A Di Ciaula","year":"2021","unstructured":"Di Ciaula A, Calamita G, Shanmugam H, Khalil M, Bonfrate L, Wang DQ, Baffy G, Portincasa P (2021) Mitochondria matter: systemic aspects of nonalcoholic fatty liver disease (NAFLD) and diagnostic assessment of liver function by stable isotope dynamic breath tests. Int J Mol Sci 22(14):7702. https:\/\/doi.org\/10.3390\/ijms22147702","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3203_CR83","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S2468-1253(20)30294-6","volume":"6","author":"G Shiha","year":"2021","unstructured":"Shiha G, Korenjak M, Eskridge W, Casanovas T, Velez-Moller P, Hogstrom S, Richardson B, Munoz C, Sigurethardottir S, Coulibaly A, Milan M, Bautista F, Leung NWY, Mooney V, Obekpa S, Bech E, Polavarapu N, Hamed AE, Radiani T, Purwanto E, Bright B, Ali M, Dovia CK, McColaugh L, Koulla Y, Dufour JF, Soliman R, Eslam M (2021) Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol 6(1):73\u201379. https:\/\/doi.org\/10.1016\/S2468-1253(20)30294-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3203_CR84","doi-asserted-by":"publisher","first-page":"155246","DOI":"10.1016\/j.metabol.2022.155246","volume":"134","author":"L Valenzuela-Vallejo","year":"2022","unstructured":"Valenzuela-Vallejo L, Mantzoros CS (2022) Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD). Metab Clin Exp 134:155246. https:\/\/doi.org\/10.1016\/j.metabol.2022.155246","journal-title":"Metab Clin Exp"},{"issue":"11","key":"3203_CR85","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1002\/hep4.1765","volume":"5","author":"SA Alqahtani","year":"2021","unstructured":"Alqahtani SA, Paik JM, Biswas R, Arshad T, Henry L, Younossi ZM (2021) Poor awareness of liver disease among adults with NAFLD in the United States. Hepatol Commun 5(11):1833\u20131847","journal-title":"Hepatol Commun"},{"key":"3203_CR86","doi-asserted-by":"publisher","DOI":"10.2057\/mtod.2022.14","author":"A Lonardo","year":"2022","unstructured":"Lonardo A, Singal AK, Osna N, Kharbanda KK (2022) Effect of cofactors on NAFLD\/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction. Metab Target Organ Damage. https:\/\/doi.org\/10.2057\/mtod.2022.14","journal-title":"Metab Target Organ Damage"},{"issue":"3","key":"3203_CR87","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/hep.31420","volume":"73","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, Cohen DE, Loomba R (2021) From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology 73(3):1194\u20131198. https:\/\/doi.org\/10.1002\/hep.31420","journal-title":"Hepatology"},{"issue":"1","key":"3203_CR88","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jhep.2021.04.021","volume":"75","author":"N Mendez-Sanchez","year":"2021","unstructured":"Mendez-Sanchez N, Diaz-Orozco L, Cordova-Gallardo J (2021) Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience. J Hepatol 75(1):221\u2013222. https:\/\/doi.org\/10.1016\/j.jhep.2021.04.021","journal-title":"J Hepatol"},{"issue":"2","key":"3203_CR89","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jhep.2021.05.003","volume":"75","author":"Y Nan","year":"2021","unstructured":"Nan Y, An J, Bao J, Chen H, Chen Y, Ding H, Dou X, Duan Z, Fan J, Gao Y, Han T, Han Y, Hu P, Huang Y, Huang Y, Jia J, Jiang J, Jiang Y, Li J, Li J, Li R, Li S, Li W, Li Y, Lin S, Liu J, Liu S, Lu L, Lu Q, Luo X, Ma X, Rao H, Ren H, Ren W, Shang J, Shi L, Su M, Wang B, Wang R, Wei L, Wen Z, Wu B, Wu J, Xin S, Xing H, Xu J, Yan M, Yang J, Yang J, Yang L, Yang Y, Yu Y, Zhang L, Zhang L, Zhang X, Zhang Y, Zhang Y, Zhao J, Zhao S, Zheng H, Zhou Y, Zhou Y, Zhuang H, Zuo W, Xu X, Qiao L (2021) The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol 75(2):454\u2013461. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.003","journal-title":"J Hepatol"},{"issue":"6","key":"3203_CR90","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J (2020) The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 14(6):889\u2013919. https:\/\/doi.org\/10.1007\/s12072-020-10094-2","journal-title":"Hepatol Int"},{"issue":"1","key":"3203_CR91","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S2468-1253(20)30213-2","volume":"6","author":"G Shiha","year":"2021","unstructured":"Shiha G, Alswat K, Al Khatry M, Sharara AI, Ormeci N, Waked I, Benazzouz M, Al-Ali F, Hamed AE, Hamoudi W, Attia D, Derbala M, Sharaf-Eldin M, Al-Busafi SA, Zaky S, Bamakhrama K, Ibrahim N, Ajlouni Y, Sabbah M, Salama M, Anushiravani A, Afredj N, Barakat S, Hashim A, Fouad Y, Soliman R (2021) Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol 6(1):57\u201364. https:\/\/doi.org\/10.1016\/S2468-1253(20)30213-2","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"3203_CR92","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41575-020-0316-6","volume":"17","author":"H Tilg","year":"2020","unstructured":"Tilg H, Effenberger M (2020) From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol 17(7):387\u2013388. https:\/\/doi.org\/10.1038\/s41575-020-0316-6","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"3203_CR93","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.14548","volume":"40","author":"S Lin","year":"2020","unstructured":"Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, Wu Y, Wang X, Zhu Y (2020) Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 40(9):2082\u20132089. https:\/\/doi.org\/10.1111\/liv.14548","journal-title":"Liver Int"},{"issue":"12","key":"3203_CR94","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/liv.14675","volume":"40","author":"S Yamamura","year":"2020","unstructured":"Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, Takahashi H, Anzai K, George J, Torimura T (2020) MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int 40(12):3018\u20133030. https:\/\/doi.org\/10.1111\/liv.14675","journal-title":"Liver Int"},{"issue":"5","key":"3203_CR95","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/s2468-1253(20)30091-1","volume":"5","author":"The Lancet G Hepatology","year":"2020","unstructured":"The Lancet G Hepatology (2020) Redefining non-alcoholic fatty liver disease: what\u2019s in a name? Lancet Gastroenterol Hepatol 5(5):419. https:\/\/doi.org\/10.1016\/s2468-1253(20)30091-1","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"3203_CR96","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/hepr.13706","volume":"52","author":"T Kawaguchi","year":"2022","unstructured":"Kawaguchi T, Tsutsumi T, Nakano D, Torimura T (2022) MAFLD: Renovation of clinical practice and disease awareness of fatty liver. Hepatol Res 52(5):422\u2013432. https:\/\/doi.org\/10.1111\/hepr.13706","journal-title":"Hepatol Res"},{"issue":"5","key":"3203_CR97","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1136\/gutjnl-2021-325102","volume":"71","author":"H Park","year":"2022","unstructured":"Park H, Yoon EL, Cho S, Jun DW, Nah E-H (2022) Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease. Gut 71(5):1035\u20131036","journal-title":"Gut"},{"key":"3203_CR98","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01650-1","volume-title":"Is metabolic syndrome responsible for the progression from NAFLD to NASH in non-obese patients?","author":"T Kawaguchi","year":"2020","unstructured":"Kawaguchi T, Torimura T (2020) Is metabolic syndrome responsible for the progression from NAFLD to NASH in non-obese patients? Springer"},{"issue":"1","key":"3203_CR99","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/hepr.13572","volume":"51","author":"Y Ochiai","year":"2021","unstructured":"Ochiai Y, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Muraishi N, Kajiwara A, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H (2021) Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease. Hepatol Res 51(1):62\u201368. https:\/\/doi.org\/10.1111\/hepr.13572","journal-title":"Hepatol Res"},{"issue":"6","key":"3203_CR100","doi-asserted-by":"publisher","first-page":"876","DOI":"10.14309\/ajg.0000000000000607","volume":"115","author":"L Xu","year":"2020","unstructured":"Xu L, Xie J, Chen S, Chen Y, Yang H, Miao M, Zhu Z, Li Y, Yu C, Xu C (2020) Light-to-moderate alcohol consumption is associated with increased risk of type 2 diabetes in individuals with nonalcoholic fatty liver disease: a nine-year cohort study. Off J Am College Gastroenterol ACG 115(6):876\u2013884","journal-title":"Off J Am College Gastroenterol ACG"},{"issue":"2","key":"3203_CR101","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/hep.30226","volume":"70","author":"K Hajifathalian","year":"2019","unstructured":"Hajifathalian K, Torabi Sagvand B, McCullough AJ (2019) Effect of alcohol consumption on survival in nonalcoholic fatty liver disease: a national prospective cohort study. Hepatology 70(2):511\u2013521. https:\/\/doi.org\/10.1002\/hep.30226","journal-title":"Hepatology"},{"issue":"1","key":"3203_CR102","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/hep.30170","volume":"69","author":"Y Chang","year":"2019","unstructured":"Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung HS, Yun KE, Shin H, Ryu S (2019) Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology 69(1):64\u201375. https:\/\/doi.org\/10.1002\/hep.30170","journal-title":"Hepatology"},{"issue":"13","key":"3203_CR103","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1056\/NEJMra1715733","volume":"379","author":"D Fuster","year":"2018","unstructured":"Fuster D, Samet JH (2018) Alcohol use in patients with chronic liver disease. New Engl J Med 379(13):1251\u20131261","journal-title":"New Engl J Med"},{"issue":"2","key":"3203_CR104","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/hep.30857","volume":"71","author":"HS Choi","year":"2020","unstructured":"Choi HS, Brouwer WP, Zanjir WM, de Man RA, Feld JJ, Hansen BE, Janssen HL, Patel K (2020) Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. Hepatology 71(2):539\u2013548","journal-title":"Hepatology"},{"issue":"8","key":"3203_CR105","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/hepr.13677","volume":"51","author":"T Tada","year":"2021","unstructured":"Tada T, Nishimura T, Matono T, Yoshida M, Yuri M, Fujiwara A, Yuri Y, Takashima T, Aizawa N, Ikeda N, Enomoto H, Kumada T, Iijima H (2021) Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Hepatol Res 51(8):860\u2013869. https:\/\/doi.org\/10.1111\/hepr.13677","journal-title":"Hepatol Res"},{"issue":"2","key":"3203_CR106","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s12072-021-10157-y","volume":"15","author":"GTS Guerreiro","year":"2021","unstructured":"Guerreiro GTS, Longo L, Fonseca MA, de Souza VEG, Alvares-da-Silva MR (2021) Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? Hepatol Int 15(2):380\u2013391","journal-title":"Hepatol Int"},{"issue":"6","key":"3203_CR107","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s00535-011-0370-5","volume":"46","author":"N Tanaka","year":"2011","unstructured":"Tanaka N, Horiuchi A, Yokoyama T, Kaneko G, Horigome N, Yamaura T, Nagaya T, Komatsu M, Sano K, Miyagawa S, Aoyama T, Tanaka E (2011) Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy. J Gastroenterol 46(6):758\u2013768. https:\/\/doi.org\/10.1007\/s00535-011-0370-5","journal-title":"J Gastroenterol"},{"issue":"6","key":"3203_CR108","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s40264-018-00790-2","volume":"42","author":"L Pavlik","year":"2019","unstructured":"Pavlik L, Regev A, Ardayfio PA, Chalasani NP (2019) Drug-induced steatosis and steatohepatitis: the search for novel serum biomarkers among potential biomarkers for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Drug Saf 42(6):701\u2013711","journal-title":"Drug Saf"},{"issue":"9","key":"3203_CR109","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/hepr.13540","volume":"50","author":"Y Sasamori","year":"2020","unstructured":"Sasamori Y, Tanaka A, Ayabe T (2020) Liver disease in pregnancy. Hepatol Res 50(9):1015\u20131023. https:\/\/doi.org\/10.1111\/hepr.13540","journal-title":"Hepatol Res"},{"key":"3203_CR110","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C (2006) The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:33. https:\/\/doi.org\/10.1186\/1471-230X-6-33","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"3203_CR111","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1111\/liv.14620","volume":"40","author":"C Bianco","year":"2020","unstructured":"Bianco C, Romeo S, Petta S, Long MT, Valenti L (2020) MAFLD vs NAFLD: let the contest begin! Liver Int 40(9):2079\u20132081. https:\/\/doi.org\/10.1111\/liv.14620","journal-title":"Liver Int"},{"issue":"3","key":"3203_CR112","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jhep.2022.01.015","volume":"77","author":"J Xie","year":"2022","unstructured":"Xie J, Lu L, Chen Y, Xu L, Xu C (2022) A simpler definition of MAFLD better predicts long-term all-cause mortality in American adults. J Hepatol 77(3):877\u2013879. https:\/\/doi.org\/10.1016\/j.jhep.2022.01.015","journal-title":"J Hepatol"},{"issue":"6","key":"3203_CR113","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","volume":"75","author":"D Kim","year":"2021","unstructured":"Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A (2021) Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol 75(6):1284\u20131291. https:\/\/doi.org\/10.1016\/j.jhep.2021.07.035","journal-title":"J Hepatol"},{"issue":"3","key":"3203_CR114","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C (2016) Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 65(3):589\u2013600. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.013","journal-title":"J Hepatol"},{"issue":"11","key":"3203_CR115","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/hepr.13685","volume":"51","author":"T Tsutsumi","year":"2021","unstructured":"Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, Koseki M, Yoshinaga S, Takahashi H, Anzai K, George J, Torimura T (2021) MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res 51(11):1115\u20131128. https:\/\/doi.org\/10.1111\/hepr.13685","journal-title":"Hepatol Res"},{"issue":"9","key":"3203_CR116","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2468-1253(21)00132-1","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam M, Ahmed A, Despres JP, Jha V, Halford JCG, Wei Chieh JT, Harris DCH, Nangaku M, Colagiuri S, Targher G, Joshi S, Byrne CD, Khunti K, Nguyen MH, Gish RG, George J (2021) Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol 6(9):743\u2013753. https:\/\/doi.org\/10.1016\/S2468-1253(21)00132-1","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"3203_CR117","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/liv.15139","volume":"42","author":"I Ayada","year":"2022","unstructured":"Ayada I, van Kleef LA, Alferink LJM, Li P, de Knegt RJ, Pan Q (2022) Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups. Liver Int 42(2):277\u2013287. https:\/\/doi.org\/10.1111\/liv.15139","journal-title":"Liver Int"},{"issue":"2","key":"3203_CR118","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/hep.32131","volume":"75","author":"LA van Kleef","year":"2022","unstructured":"van Kleef LA, Ayada I, Alferink LJM, Pan Q, de Knegt RJ (2022) Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: the rotterdam study. Hepatology 75(2):419\u2013429. https:\/\/doi.org\/10.1002\/hep.32131","journal-title":"Hepatology"},{"issue":"1","key":"3203_CR119","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2468-1253(20)30340-X","volume":"6","author":"N Mendez-Sanchez","year":"2021","unstructured":"Mendez-Sanchez N, Arrese M, Gadano A, Oliveira CP, Fassio E, Arab JP, Chavez-Tapia NC, Dirchwolf M, Torre A, Ridruejo E, Pinchemel-Cotrim H, Castellanos Fernandez MI, Uribe M, Girala M, Diaz-Ferrer J, Restrepo JC, Padilla-Machaca M, Dagher L, Gatica M, Olaechea B, Pessoa MG, Silva M (2021) The Latin American association for the study of the liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol 6(1):65\u201372. https:\/\/doi.org\/10.1016\/S2468-1253(20)30340-X","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"3203_CR120","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, Marcus C, Lee WS, Kelly D, Porta G, El-Guindi MA, Alisi A, Mann JP, Mouane N, Baur LA, Dhawan A, George J (2021) Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol 6(10):864\u2013873. https:\/\/doi.org\/10.1016\/S2468-1253(21)00183-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3203_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.08.027","author":"G Shiha","year":"2022","unstructured":"Shiha G, Korenjak M, Casanovas T, Mooney V, Sigurethardottir S, Koulla Y, Soliman R (2022) MAFLD 2022: an ELPA\/ALPA\/EASO-ECPO joint statement on disease stigma. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.027","journal-title":"J Hepatol"},{"issue":"3","key":"3203_CR122","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/MOG.0000000000000823","volume":"38","author":"J Alharthi","year":"2022","unstructured":"Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M (2022) Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol 38(3):251\u2013260. https:\/\/doi.org\/10.1097\/MOG.0000000000000823","journal-title":"Curr Opin Gastroenterol"},{"issue":"5","key":"3203_CR123","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jhep.2020.12.035","volume":"74","author":"Y Fouad","year":"2021","unstructured":"Fouad Y, Gomaa A, Semida N, Ghany WA, Attia D (2021) Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. J Hepatol 74(5):1254\u20131256. https:\/\/doi.org\/10.1016\/j.jhep.2020.12.035","journal-title":"J Hepatol"},{"issue":"10319","key":"3203_CR124","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","volume":"399","author":"TH Karlsen","year":"2022","unstructured":"Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Jarvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Gines P, Buti M, Newsome PN, Burra P, Manns MP (2022) The EASL-lancet liver commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399(10319):61\u2013116. https:\/\/doi.org\/10.1016\/S0140-6736(21)01701-3","journal-title":"Lancet"},{"issue":"6","key":"3203_CR125","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1007\/s12072-022-10407-7","volume":"16","author":"H Lee","year":"2022","unstructured":"Lee H, Lim TS, Kim SU, Kim HC (2022) Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population. Hepatol Int 16(6):1308\u20131317. https:\/\/doi.org\/10.1007\/s12072-022-10407-7","journal-title":"Hepatol Int"},{"issue":"9","key":"3203_CR126","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","volume":"107","author":"KE Chan","year":"2022","unstructured":"Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, Tan DJH, Lim WH, Lin SY, Huang D, Chan M, Khoo CM, Chew NWS, Kaewdech A, Chamroonkul N, Dan YY, Noureddin M, Muthiah M, Eslam M, Ng CH (2022) Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin EndocrinolMetab 107(9):2691\u20132700. https:\/\/doi.org\/10.1210\/clinem\/dgac321","journal-title":"J Clin EndocrinolMetab"},{"issue":"10","key":"3203_CR127","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.dld.2021.05.014","volume":"53","author":"A Mantovani","year":"2021","unstructured":"Mantovani A (2021) MAFLD vs NAFLD: where are we? Dig Liver Dis 53(10):1368\u20131372","journal-title":"Dig Liver Dis"},{"issue":"3","key":"3203_CR128","doi-asserted-by":"publisher","first-page":"85","DOI":"10.37349\/emed.2020.00007","volume":"1","author":"A Lonardo","year":"2020","unstructured":"Lonardo A, Ballestri S (2020) Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Explor Med 1(3):85\u2013107. https:\/\/doi.org\/10.37349\/emed.2020.00007","journal-title":"Explor Med"},{"issue":"7","key":"3203_CR129","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, Lee HS (2010) Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 42(7):503\u2013508. https:\/\/doi.org\/10.1016\/j.dld.2009.08.002","journal-title":"Dig Liver Dis"},{"issue":"4","key":"3203_CR130","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.cgh.2020.05.034","volume":"19","author":"DH Lee","year":"2021","unstructured":"Lee DH, Cho EJ, Bae JS, Lee JY, Yu SJ, Kim H, Lee KB, Han JK, Choi BI (2021) Accuracy of two-dimensional shear wave elastography and attenuation imaging for evaluation of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 19(4):797-805 e797. https:\/\/doi.org\/10.1016\/j.cgh.2020.05.034","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"3203_CR131","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10396-021-01106-1","volume":"48","author":"G Ferraioli","year":"2021","unstructured":"Ferraioli G (2021) Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens). J Med Ultrason 48(4):489\u2013495. https:\/\/doi.org\/10.1007\/s10396-021-01106-1","journal-title":"J Med Ultrason"},{"issue":"4","key":"3203_CR132","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11695-010-0204-1","volume":"21","author":"ZM Younossi","year":"2011","unstructured":"Younossi ZM, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N, Afendy A, Younoszai Z, Goodman Z, Baranova A (2011) A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obesity Surg 21(4):431\u2013439. https:\/\/doi.org\/10.1007\/s11695-010-0204-1","journal-title":"Obesity Surg"},{"issue":"5","key":"3203_CR133","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R (2019) Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156(5):1264-1281 e1264. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.036","journal-title":"Gastroenterology"},{"issue":"1","key":"3203_CR134","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1002\/ctd2.9","volume":"1","author":"A Lonardo","year":"2021","unstructured":"Lonardo A (2021) Back to the future: from the history of NAFLD to MAFLD to heterogeneity of disease. Clin Transl Discov 1(1):e9. https:\/\/doi.org\/10.1002\/ctd2.9","journal-title":"Clin Transl Discov"},{"issue":"3","key":"3203_CR135","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2174\/156652409787847191","volume":"9","author":"SA Polyzos","year":"2009","unstructured":"Polyzos SA, Kountouras J, Zavos C (2009) Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 9(3):299\u2013314. https:\/\/doi.org\/10.2174\/156652409787847191","journal-title":"Curr Mol Med"},{"key":"3203_CR136","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312620","author":"S Passarella","year":"2021","unstructured":"Passarella S, Schurr A, Portincasa P (2021) Mitochondrial transport in glycolysis and gluconeogenesis: achievements and perspectives. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222312620","journal-title":"Int J Mol Sci"},{"issue":"15","key":"3203_CR137","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.3390\/jcm10153445","volume":"10","author":"SM Schmitz","year":"2021","unstructured":"Schmitz SM, Schooren L, Kroh A, Koch A, Stier C, Neumann UP, Ulmer TF, Alizai PH (2021) Association of body composition and sarcopenia with NASH in obese patients. J Clin Med 10(15):3445. https:\/\/doi.org\/10.3390\/jcm10153445","journal-title":"J Clin Med"},{"key":"3203_CR138","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fphys.2019.00042","volume":"10","author":"JH Lee","year":"2019","unstructured":"Lee JH, Jun HS (2019) Role of myokines in regulating skeletal muscle mass and function. Front Physiol 10:42. https:\/\/doi.org\/10.3389\/fphys.2019.00042","journal-title":"Front Physiol"},{"issue":"10","key":"3203_CR139","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1210\/jc.2018-01056","volume":"103","author":"N Perakakis","year":"2018","unstructured":"Perakakis N, Mougios V, Fatouros I, Siopi A, Draganidis D, Peradze N, Ghaly W, Mantzoros CS (2018) Physiology of activins\/follistatins: associations with metabolic and anthropometric variables and response to exercise. J Clin Endocrinol Metab 103(10):3890\u20133899. https:\/\/doi.org\/10.1210\/jc.2018-01056","journal-title":"J Clin Endocrinol Metab"},{"key":"3203_CR140","doi-asserted-by":"publisher","first-page":"103584","DOI":"10.1016\/j.ebiom.2021.103584","volume":"72","author":"F Bril","year":"2021","unstructured":"Bril F (2021) What the new definition of metabolic dysfunction-associated fatty liver disease (MAFLD) left behind: genetically acquired fatty liver disease (GAFLD). EBioMedicine 72:103584. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103584","journal-title":"EBioMedicine"},{"issue":"3","key":"3203_CR141","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nrendo.2010.199","volume":"7","author":"CG Fiorenza","year":"2011","unstructured":"Fiorenza CG, Chou SH, Mantzoros CS (2011) Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol 7(3):137\u2013150. https:\/\/doi.org\/10.1038\/nrendo.2010.199","journal-title":"Nat Rev Endocrinol"},{"issue":"26","key":"3203_CR142","doi-asserted-by":"publisher","first-page":"8393","DOI":"10.3748\/wjg.v20.i26.8393","volume":"20","author":"N Toshikuni","year":"2014","unstructured":"Toshikuni N, Tsutsumi M, Arisawa T (2014) Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World J Gastroenterol: WJG 20(26):8393\u20138406. https:\/\/doi.org\/10.3748\/wjg.v20.i26.8393","journal-title":"World J Gastroenterol: WJG"},{"issue":"42","key":"3203_CR143","doi-asserted-by":"publisher","first-page":"e22805","DOI":"10.1097\/MD.0000000000022805","volume":"99","author":"S Chalasani","year":"2020","unstructured":"Chalasani S, Mathur K, Shammas N, Orman E, Vuppalanchi R, Lammert C (2020) Hepatic steatosis is highly prevalent but is not correlated with stiffness in autoimmune hepatitis. Medicine (Baltimore) 99(42):e22805. https:\/\/doi.org\/10.1097\/MD.0000000000022805","journal-title":"Medicine (Baltimore)"},{"issue":"46","key":"3203_CR144","doi-asserted-by":"publisher","first-page":"12989","DOI":"10.3748\/wjg.v21.i46.12989","volume":"21","author":"Y Haga","year":"2015","unstructured":"Haga Y, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O (2015) Nonalcoholic fatty liver disease and hepatic cirrhosis: comparison with viral hepatitis-associated steatosis. World J Gastroenterol: WJG 21(46):12989\u201312995. https:\/\/doi.org\/10.3748\/wjg.v21.i46.12989","journal-title":"World J Gastroenterol: WJG"},{"issue":"12","key":"3203_CR145","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1530\/EC-18-0499","volume":"7","author":"C Krause","year":"2018","unstructured":"Krause C, Grohs M, El Gammal AT, Wolter S, Lehnert H, Mann O, Mittag J, Kirchner H (2018) Reduced expression of thyroid hormone receptor beta in human nonalcoholic steatohepatitis. Endocr Connect 7(12):1448\u20131456. https:\/\/doi.org\/10.1530\/EC-18-0499","journal-title":"Endocr Connect"},{"issue":"15","key":"3203_CR146","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.3390\/nu14153112","volume":"14","author":"M Khalil","year":"2022","unstructured":"Khalil M, Shanmugam H, Abdallah H, John Britto JS, Galerati I, Gomez-Ambrosi J, Fruhbeck G, Portincasa P (2022) The potential of the mediterranean diet to improve mitochondrial function in experimental models of obesity and metabolic syndrome. Nutrients 14(15):3112. https:\/\/doi.org\/10.3390\/nu14153112","journal-title":"Nutrients"},{"key":"3203_CR147","doi-asserted-by":"publisher","first-page":"154708","DOI":"10.1016\/j.metabol.2021.154708","volume":"117","author":"M Longo","year":"2021","unstructured":"Longo M, Meroni M, Paolini E, Macchi C, Dongiovanni P (2021) Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending? Metab Clin Exp 117:154708. https:\/\/doi.org\/10.1016\/j.metabol.2021.154708","journal-title":"Metab Clin Exp"}],"updated-by":[{"DOI":"10.1007\/s11739-023-03252-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000}}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-023-03203-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-023-03203-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-023-03203-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T11:23:03Z","timestamp":1691752983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-023-03203-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":147,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["3203"],"URL":"https:\/\/doi.org\/10.1007\/s11739-023-03203-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11739-023-03252-5","asserted-by":"object"}]},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]},"assertion":[{"value":"8 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11739-023-03252-5","URL":"https:\/\/doi.org\/10.1007\/s11739-023-03252-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The article is a review analysis. Human Participants and\/or Animals have not been involved in the present study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement and Informed consent"}}]}}